Haematology Research

The Concord Haematology Department delivers world-class tertiary Haematology clinical care, supported by active clinical, translational, and basic research. As one of the largest Haematology Clinical Research Units in NSW, we have recruited over 1000 patients to more than 140 trials since 2005.

Our Clinical Research Unit is led by Dr Nicole Wong Doo (Director), Jennfer Harman (Manager) and Tafline Walker (Business Operations Manager). Our unit is staffed by a Clinical Coordination Division of five Registered Nurses and five Clinical Research Coordinators, all with tertiary science qualifications. Our highly skilled Business Operations Division efficiently meet our regulatory and reporting obligations, and support the team in various high-level administrative functions, in clinical trials governance and financial management. Ten haematologist investigators are supported by several clinical research fellows.

Our broad portfolio with 28 currently recruiting trials and 32 trials in follow-up is particularly strong in trials in lymphoproliferative diseases. As a national leader in accessing emerging therapies, our unit has a high proportion of patients referred for clinical trial participation both within Sydney and across NSW and ACT.

Our Key Research Themes and Achievements

Australasian Leukaemia Lymphoma Group (ALLG) studies

Basic and translational research

ClinTrial Refer App

Engaging medical students in research

High impact publications

International Waldenström Macroglobulinaemia (WM) Study

Leadership in clinical trials

Concord Haematology are leaders and internationally recognised in the areas of patient-reported outcomes research, cancer survivorship and patterns of care research in myeloma and lymphoma.

Professor Judith Trotman and Dr Nicole Wong Doo are the co-Australian PIs of the RADAR study, an international collaborative trial in early-stage Hodgkin Lymphoma with University College London, and with $1.3M in funding from the Australian Medical Research Future Fund (MRFF). In 2023, Concord was activated as the first site for RADAR.

Dr Robin Gasiorowski is the PrincipaI Investigator of two industry trials of the novel bispecific antibody, epcoritamab, for patients with relapsed lymphoma. Data from the phase 2 trial was published in the Journal of Clinical Oncology in April 2023, and subsequently led to drug approval in Europe and the USA. Dr Gasiorowski presented updated data from this study as an oral presentation at the 2023 Blood Conference in Melbourne.

Dr Emma Verner is the PrincipaI Investigator of the international, industry-sponsored Phase I trial of sonrotoclax, an oral Bcl-2 inhibitor for patients with mature B-Cell Malignancies. Data from this trial has been presented at various international conferences throughout 2023, including the ASH Annual Meeting in San Diego, USA, the Spanish Society of Hematology and Hemotherapy in Seville, Spain and the Annual Congress of the Fresh Haematology Society in Paris, France. The data has been published in Blood with Dr Verner presenting at the 2023 Blood Conference in Melbourne.

Dr Brendan Beaton, Dr Katherine Rankin and Professor Trotman led the investigator-initiated trial in the efficacy of COVID-19 vaccination in people with Follicular Lymphoma and Waldenström Macroglobulinaemia, with 2023 publications in the American Journal of Hematology, and European Journal of Haematology. Funding for this study was supported by our Clinical Research Unit via the Foundation for A Bloody Great Cause and lymphoma patient organisations: Lymphoma Australia and the IWMF (International Waldenström Macroglobulinaemia Foundation).

Dr Nicole Wong Doo, Dr Janlyn Falconer and 2023 Clinical Research Unit Fellow Dr Patrick Tunney are developing the "My Hodgkin My Health" smartphone App for long-term follow-up of patients with Hodgkin Lymphoma, with funding support from the Clinical Research Unit.

Professor Trotman and Dr Wong Doo co-chaired the Federal Government-commissioned Optimal Care Pathway for Low Grade Lymphomas and a separate Optimal Care Pathway for Waldenström Macroglobulinaemia (to be published in 2024).

Patient-reported outcomes research, cancer survivorship and patterns of care research

Promoting research with patient organisations

Patient and Community Philanthropic Support

The Haematology Clinical Research Unit is supported by the Foundation for a Bloody Great Cause and their fundraising arm, the Bloody Great Committee. 2023 saw the introduction of our inaugural Bloody Great Fellow, Dr Monique Menzies-Wojtowicz, and the return of Patient Information Day, which saw over 100 patients and families attend talks by our haematologists, the Head of Infectious Diseases Associate Professor Tom Gottlieb, pharmacists, nurses and allied health professionals. Through the tremendous support of the local community, the Foundation/Committee raised over $200,000 in 2023, allowing the Unit the financial independence to support investigator-initiated and collaborative group trials and translational research.

MyHodgkin MyHealth

Help advance Hodgkin lymphoma research

Are you a patient with Hodgkin lymphoma, either now or in the past?

If so, join us to test the MyHodgkin MyHealth App to improve understanding of the long-term consequences of Hodgkin lymphoma treatments.

Long-term survival rates for people diagnosed with Hodgkin lymphoma are better than ever, but with significant changes to treatment over the last decade, more information is needed to further understand the longer-term consequences of these treatments.
Find out more

Our Research Team

Professor Judith Trotman	Head of Department, Consultant Haematologist
Dr Nicole Wong Doo	Haematology Clinical Research Unit Director, Consultant Haematologist
Associate Professor Vivien Chen	Head Basic and Translational Research, Consultant Haematologist
Associate Professor Ilona Cunningham	SLHD Clinical Director Cancer and Palliative Care, Consultant Haematologist
Dr Robin Gasiorowski	Consultant Haematologist
Dr Emma Verner	Consultant Haematologist
Dr Janlyn Falconer	Consultant Haematologist
Dr Ibrahim Tohidi-Esfahani	Consultant Haematologist
Dr Marc Ellis	Consultant Haematologist
Dr Praveen Gounder	Locum, Consultant Haematologist
Dr Monique Menzies-Wojtowicz	MBBS Clinical Trials Fellow
Dr Patrick Tunney	Clinical Trials Fellow
Dr Ke Xu	Clinical Trials Fellow
Jennifer Harman	Clinical Nurse Specialist, Clinical Research Unit Manager
Adeline Kintono	Clinical Trial Coordinator and Registered Nurse
Alexander Wong	Clinical Trial Coordinator
Andrea Salangsang	Clinical Trial Coordinator and Registered Nurse
Lailamaryam Alkhouri	Clinical Trial Coordinator
Mili Patel	Clinical Trial Coordinator
Nathan Zhou	Clinical Trial Coordinator
Raquel Hermosilla	Clinical Trial Coordinator
Sarandar Kumar	Clinical Trial Coordinator
Sylvia Chan	Clinical Trial Coordinator and Registered Nurse
Trieu Huynh	Clinical Trial Coordinator and Registered Nurse
Tafline Walker	Business Operations Manager
Alfredo Inton	Administration Officer
Amanda Li	Administration Officer
Georgia Klemm	Administration Officer
Ekaterina Jebelev	Administration Officer

Selected Grants

Amount awarded	Grant and project details
$5,000,000	NHMRC Synergy Grant, 2020-2024 Addressing Australia’s National Transfusion Research Priorities Investigators: Trotman J (CIG)
$2,900,000	MRFF, 2021-2024 A national, multi-centre study evaluating Thrombotic Thrombocytopenia Syndrome (TTS) associated with ChAdOx1 (AZD1222) and other SARS-CoV-2 vaccines (viral vector & m-RNA) Investigators: Chen V, Tran, Passam, Phan, Wood, MacFadyen, Monagle
$2,752,967	MRFF, 2022-2026 Comparing Immunisation-boosting Regimens for COVID-19 Upon Initiation of immunosuppressive Therapies (CIRCUIT Study). Investigators: Sasson S, Kelleher A, Petoumenos K, Davenport M, Trotman J, Brilot F, Turville S, Hamad N, Bull R, Ahlenstiel G
$2,490,422	NHMRC, 2021-2026 Preventing infections in patients with blood cancer through evidence-based use of immunoglobulin or alternatives: The RATIONALISE trial Investigators: Wood E (CIA), McQuilten Z (CIB), Morrissey CO (CIC), Trotman J (CID), Spencer A (CIE), Opat S (CIF), Fanning L (CIG), Reynolds J (CIH), Paterson D (CII), Mulligan S (CIJ)
$1,395,000	MRFF, 2021-2026 RADAR: A randomised PET-adapted study of bleomycin-free treatment of early-stage Hodgkin Lymphoma. Investigators: Trotman J, Wong Doo N, Radford J, Berkahn L, Barrington S, Gandhi M, Opat S, Hawkes E, Cochrane T, Johnston A
$1,225,487	MRFF, 2021-2026 Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma. Investigators: Hawkes E, Trotman J, Savage K, Keane C, Lee ST, Kuruvilla J, Cochrane T, Cheah CY, Gregory G, Johnston A
$1,000,000	NSW Cardiovascular Collaborative Grant, 2023-2025 Mechanisms of Vascular Thrombosis. Investigators: Chen V, Passam F, Chong B, Pasalic L, Lee C, Leung H, Tohidi-Esfahani I
$659,293	MRFF, 2022-2024 Discovery of new platelet targets to improve the management of coronary artery disease. Investigators: Passam F, Chen V, Weaver, Larance.
$193,000	NFMRI, 2022-2024 Novel Biomarker to predict thrombotic risk in myeloproliferative neoplasms. Investigator: Chen V

Previous Grants

Amount awarded	Grant and project details
$1,192,947	NHMRC Ideas, 2020-2023 Inhibition of the platelet thrombin receptor PAR4 to prevent thrombosis in coronary artery disease Investigators: Hamilton J (CIA), Chen V
$1,057,839	MRFF ICTP, 2020-2023 Apixaban Twice Daily vs Rivaroxaban Once Daily for the Treatment of Venous Thromboembolism: A randomised controlled trial (COBRRA) Investigators: Chen V
$787,000	MRFF RCRDUN Grant, 2019-2023 PETReA Study Investigators: Trotman J

Our Publications

2023

Adattini JA, Gross AS, Doo NW, McLachlan AJ. Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia. Haematologica. 2023 Aug 1;108(8):2224-2228. doi: 10.3324/haematol.2022.282237.

Al-Mashhadi AL, Simonsen MR, Cheah CY, Amini RM, Arboe B, Cerhan JR, Chanchiri I, Clausen MR, Day J, Eyre TA, Ortved Gang A, Ghesquieres H, Habermann TM, Hawkes EA, Hwang SR, Jørgensen JB, Khurana A, Maquet C, Layshe N, Opat SS, El-Galaly TC. Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up. Blood. 2023 Nov 28; 142(1): 4396. https://doi.org/10.1182/blood-2023-173247

Amaador K, Thieblemont C, Trotman J, Minnema MC. Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia. Hematol Oncol. 2023 Jul 17. doi: 10.1002/hon.3210. Epub ahead of print.

Baggio D, Wellard C, Chung E, Talaulikar D, Keane C, Opat S, Giri P, Minson A, Cheah CY, Armytage T, Lee D, Chong G, Johnston A, Cochrane T, Waters N, Hamad N, Wood EM, Hawkes EA. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leuk Lymphoma. 2023 Mar;64(3):621-627. doi: 10.1080/10428194.2022.2157676. Epub 2022 Dec 21.

Baker RI, Gilmore G, Chen V, Young L, Merriman E, Curnow J, Joseph J, Tiao JY, Chih J, McRae S, Harper P, Tan CW, Brighton T, Royle G, Hugman A, Hankey GJ, Crowther H, Boey J, Gallus A, Campbell P, Tran H; Thrombosis and Haemostasis Society of Australia and New Zealand Anticoagulation Reversal and Events Study Collaborative. Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study. Res Pract Thromb Haemost. 2023 May 26;7(5):100196. doi: 10.1016/j.rpth.2023.100196.

Barraclough A, England JT, Villa D, Wight J, Hapgood G, Conn J, Doo NW, Li EW, Gilbertson M, Shaw B, Bishton MJ, Saeed M, Ratnasingam S, Abeyakoon C, Chong G, Wai SH, Ku M, Lee HP, Fleming K, Tam C, Douglas G, Cheah CY, Ng ZY, Rolfe T, Mills AK, Hamad N, Cashman H, Gleeson M, Narayana M, Hawkes EA. Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance. Haematologica. 2023 Sep 1;108(9):2444-2453. doi: 10.3324/haematol.2022.281375.

Beaton B, Sasson SC, Rankin K, Raedemaeker J, Wong A, Hastak P, Phetsouphanh C, Warden A, Klemm V, Munier CML, Hoppe AC, Tea F, Pillay A, Stella AO, Aggarwal A, Lavee O, Caterson ID, Turville S, Kelleher AD, Brilot F, Trotman J. Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses. Am J Hematol. 2023 Jan;98(1):131-139. doi: 10.1002/ajh.26619. Epub 2022 Jun 9.

Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Report of consensus panel 1 from the 11^th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. Semin Hematol. 2023 Mar;60(2):73-79. doi: 10.1053/j.seminhematol.2023.03.005. Epub 2023 Mar 29.

Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia. Future Oncology. 2023 Feb; 19(5):345-353. https://doi.org/10.2217/fon-2022-1015

Castillo JJ, Buske C, Trotman J, Sarosiek S, Treon SP. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. Am J Hematol. 2023 Feb;98(2):338-347. doi: 10.1002/ajh.26788. Epub 2023 Jan 1.

Cheah S, Bassett JK, Bruinsma FJ, Hopper J, Jayasekara H, Joshua D, MacInnis RJ, Prince HM, Southey MC, Vajdic CM, van Leeuwen MT, Wong Doo N, Harrison SJ, English DR, Giles GG, Milne RL. Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma. Expert Rev Hematol. 2023 Jul-Dec;16(10):773-783. doi: 10.1080/17474086.2023.2255747. Epub 2023 Sep 8.

Choi PY, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VMY, Merriman E, Yong ASM, Simpson J, Gardiner E, Cherbuin N, Curnow J, Pepperell D, Bird R. Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients. Res Pract Thromb Haemost. 2023 Jan;7(1):100009. doi: 10.1016/j.rpth.2022.100009. Epub 2022 Dec 13.

Clarke L, Brighton T, Chunilal SD, Lee CSM, Passam F, Curnow J, Chen VM, Tran HA. Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem. Vaccine. 2023 May 11;41(20):3285-3291. doi: 10.1016/j.vaccine.2023.03.071. Epub 2023 Apr 19.

Defrancesco I, Ferretti VV, Morel P, Kyriakou C, Kastritis E, Tohidi-Esfahani I, Tedeschi A, Buske C, García-Sanz R, Vos JMI, Peri V, Margiotta Casaluci G, Ferrari A, Piazza F, Oostvogels R, Lovato E, Montes L, Fornecker LM, Grunenberg A, Dimopoulos MA, Tam CS, D'Sa S, Leblond V, Trotman J, Passamonti F, Arcaini L, Varettoni M. SARS-CoV-2 Infection in Patients With Waldenström's Macroglobulinemia: A Multicenter International Cohort Study. Hemasphere. 2023 Jun 2;7(6):e887. doi: 10.1097/HS9.0000000000000887.

Dickinson M, Berkahn L, Trotman J, Butler J, Neeson P, Bressel M, Minson A. P1066: Pembrolizumab Monotherapy As A First Therapy For Hodgkin Lymphoma Is Deliverable In Older Or Abvd Ineligible Patients, Does Not Preclude Subsequent Therapy, And Provides Adequate Survival. HemaSphere. 2023 Aug;7(Suppl):e691267e. https://doi.org/10.1097/01.HS9.0000971160.69126.7e

Dimopoulos MA, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous J, Motta M, Siddiqi T, Tani M, Trněný M, Minnema MC, Buske C, Leblond V, Treon SP, Trotman J, Chan WY, Schneider J, Allewelt H, Patel S, Cohen A, Tam CS. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol. 2023 Nov 20;41(33):5099-5106. doi: 10.1200/JCO.22.02830. Epub 2023 Jul 21.

D'Sa S, Matous JV, Advani R, Buske C, Castillo JJ, Gatt M, Kapoor P, Kersten MJ, Leblond V, Leiba M, Palomba ML, Paludo J, Qiu L, Sarosiek S, Shadman M, Talaulikar D, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Trotman J, Varettoni M, Vos J, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Kastritis E. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients. Semin Hematol. 2023 Mar;60(2):80-89. doi: 10.1053/j.seminhematol.2023.03.003. Epub 2023 Mar 27.

Ellis ML, Alwis I, Smythe R, Yuan Y, Jackson SP. Megakaryocyte buds are distinct from microvesicles and likely to represent platelet precursors. Blood Adv. 2023 Mar 28;7(6):982-986. doi: 10.1182/bloodadvances.2022008850.

Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 Sep;29(9):548-555. doi: 10.1016/j.jtct.2023.06.012. Epub 2023 Jul 5.

Fleming S, Reynolds J, Bajel A, Venn N, Kwan J, Moore J, Yeung D, Pati N, Leahy M, Kollipara S, Verner E, Berkakn L, Sutton R, Wei A, Greenwood M. P365: Sequential blinatumomab with reduced intensity chemotherapy for older adults with newly diagnosed ph-b-precursor acute lymphoblastic leukemia-final results of the ALLG ALL08 study. HemaSphere. 2023 Aug;7(Suppl). e811479d. https://doi.org/10.1097/01.HS9.0000968372.81147.9d

Garcia-Manero G, Odenike O, Fleming S, Roboz GJ, Jacoby M, Cunningham I, Kreuzer KA, Enjeti AK, Baer MA, Cook R, Jurcic J, Ku G, Zhou Y, Hoffman D, Potluri J, Garcia JS. Combination of Venetoclax and Azacitidine in Patients with Treatment-Naive, High-Risk Myelodysplastic Syndromes with Responses Leading to Stem Cell Transplantation. Blood. 2023 Nov 02; 142(1): 1868. https://doi.org/10.1182/blood-2023-187102

Hapgood G, Civallero M, Stepanishyna Y, Vose J, Cabrera ME, Advani RH, Pileri SA, Manni M, Horwitz SM, Foss FM, Hitz F, Radford J, Dlouhy I, Chiattone C, Kim WS, Skrypets T, Nagler A, Trotman J, Luminari S, Federico M. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood Adv. 2023 Sep 12;7(17):5047-5054. doi: 10.1182/bloodadvances.2023010037.

Hawkes EA, Trotman J, Casulo C, Smith SM, LaCasce A; international Women in Lymphoma Steering Committee. Author gender representation of journal reviews and editorials on lymphoma (2017-22). Lancet. 2023 Aug 12;402(10401):523-525. doi: 10.1016/S0140-6736(23)01428-9.

Johnson N, Lavie D, Borchmann P, Gregory G, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu, Keane C, Kuruvilla J, Marceau West R, Pillai P, Marinello P, Timmerman J. P1065: Updated results from an open-label phase 1/2 study of favezelimab in combination with pembrolizumab in patients with anti-pd-1-naive relapsed or refractory classical hodgkin lymphoma. HemaSphere. 2023 Aug;7(Suppl):e0274602. https://doi.org/10.1097/01.hs9.0000971156.02746.02

Johnson NA, Lavie D, Borchmann P, Gregory GP, Herrera AF, Minuk L, Vucinic V, Armand P, Avigdor A, Gasiorowski R, Herishanu Y, Keane C, Kuruvilla J, Marceau West R, Pillai P, Marinello P, Timmerman J. A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies. Blood. 2023 Nov 28; 142(1): 1693. https://doi.org/10.1182/blood-2023-182128

Josefsson EC, Ramström S, Thaler J, Lordkipanidzé M; COAGAPO study group. Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH. J Thromb Haemost. 2023 Aug;21(8):2291-2299. doi: 10.1016/j.jtha.2023.05.001. Epub 2023 May 10.

Jurczak W, Ghesquieres H, Karimi Y, Cheah C, Clausen MR, Do YR, Lewis D, Gasiorowski R, Kim TM, Van Der Poel M, Poon ML, Feldman T, Linton K, Sureda A, Hutchings , Kanoun S, Vercellino L, Cota Stirner M, Mcgoldrick S, Liu Y, Sacchi M, Lugtenburg P, Thieblemont C. P1118: Longer follow-up from the pivotal epcore NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions in patients with relapsed/refractory large b-cell lymphoma. HemaSphere. 2023 Aug;7(Suppl). e081065c. https://doi.org/10.1097/01.HS9.0000971368.08106.5c

Karimi Y, Ghesquieres H, Jurczak W, Cheah C, Clausen M, Lugtenburg P, Do YR, Lewis DJ, Gasiorowski R, Kim TM, van der Poel M, Poon MLM, Feldman TA, Linton KM, Sureda A, Hutchings M, Cota Stirner M, Sacchi M, Thieblemont C. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. Journal of Clinical Oncology. 2023 Jun 01; 41(16), 7525-7525. https://doi.org/10.1200/JCO.2023.41.16_suppl.7525

Karimi Y, Ghesquieres H, Jurczak W, Cheah CY, Clausen MR, Lugtenburg P, Do YR, Lewis DJ, Gasiorowski R, Kim TM, van der Poel M, Poon ML, Feldman T, Linton KM, Sureda A, Hutchings M, Stirner MC, Liu Y, Kilavuz N, Thieblemont C. ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial. Clinical Lymphoma, Myeloma and Leukemia. 2023 Sep 1;23:S438. https://doi.org/10.1016/S2152-2650(23)01330-7

Kostakoglu L, Martelli M, Sehn LH, Davies A, Trněný M, Herold M, Vitolo U, Hiddemann W, Trotman J, Knapp A, Mattiello F, Nielsen TG, Sahin D, Sellam G, Ward C, Younes A. A comparison of the prognostic performance of the Lugano 2014 and RECIL 2017 response criteria in patients with NHL from the phase III GOYA and GALLIUM trials. EJHaem. 2023 Oct 9;4(4):1042-1051. doi: 10.1002/jha2.796.

Lay AJ, Dupuy A, Hagimola L, Tieng J, Larance M, Zhang Y, Yang J, Kong Y, Chiu J, Gray E, Qin Z, Schmidt D, Maclean J, Hofma B, Ellis M, Kalev-Zylinska M, Argon Y, Jackson SP, Hogg P, Passam FH. Endoplasmic reticulum protein 5 attenuates platelet endoplasmic reticulum stress and secretion in a mouse model. Blood Adv. 2023 May 9;7(9):1650-1665. doi: 10.1182/bloodadvances.2022008457.

Lee CSM, Clarke LJ, Kershaw GW, Tohidi-Esfahani I, Brighton TA, Chunilal S, Favaloro EJ, Tran H, Chen VM. Platelet-activating functional assay resolution in vaccine-induced immune thrombotic thrombocytopenia: differential alignment to PF4 ELISA platforms. Res Pract Thromb Haemost. 2023 Mar 25;7(3):100128. doi: 10.1016/j.rpth.2023.100128.

Li EW, Krishnaswamy M, El-Wahsh S, Balgobind S, Trotman J, Tan I, Hardy TA. Paraneoplastic primary CNS angiitis secondary to nodular lymphocyte predominant Hodgkin lymphoma. Pathology. 2023 Jun;55(4):547-551. doi: 10.1016/j.pathol.2022.08.012. Epub 2022 Oct 29.

Loo S, Roberts AW, Anstee NS, Kennedy GA, He S, Schwarer AP, Enjeti AK, D'Rozario J, Marlton P, Bilmon IA, Taper J, Cull G, Tiley C, Verner E, Hahn U, Hiwase DK, Iland HJ, Murphy N, Ramanathan S, Reynolds J, Ong DM, Tiong IS, Wall M, Murray M, Rawling T, Leadbetter J, Rowley L, Latimer M, Yuen S, Ting SB, Fong CY, Morris K, Bajel A, Seymour JF, Levis MJ, Wei AH. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG. Blood. 2023 Dec 7;142(23):1960-1971. doi: 10.1182/blood.2023020301.

Luminari S, Fossa A, Trotman J, Molin D, d'Amore F, Enblad G, Berkahn L, Barrington SF, Radford J, Federico M, Kirkwood AA, Johnson PWM. Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. J Clin Oncol. 2024 Jan 1;42(1):13-18. doi: 10.1200/JCO.23.01177. Epub 2023 Oct 26.

Mascuñano RC, Cheah CY, Tam CS, Lasica M, Verner E, Browett PJ, Anderson MA, Hilger J, Fang Y, Simpson D, Opat S. Phase 1 Study With the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor Sonrotoclax (BGB-11417) as Monotherapy or in Combination With Zanubrutinib for CLL/SLL: Preliminary Data. Sangre. 2023 Oct; 42(1): 268.

McKenzie CA, Gupta R, Jackett L, Anderson L, Chen V, Dahlstrom JE, Dray M, Farshid G, Hemmings C, Karim R, Kench JG, Klebe S, Kramer N, Kumarasinghe P, Maclean F, Morey A, Nguyen MA, O'Toole S, Rowbotham B, Salisbury ELC, Scolyer RA, Stewart K, Waring L, Cooper CL, Cooper WA. Looking beyond workforce parity: addressing gender inequity in pathology. Pathology. 2023 Oct;55(6):760-771. doi: 10.1016/j.pathol.2023.07.002. Epub 2023 Jul 25.

Mittal P, Quattrocchi G, Tohidi-Esfahani I, Sayar Z, Chandratheva A, Cohen H. Antiphospholipid syndrome, antiphospholipid antibodies, and stroke. Int J Stroke. 2023 Apr;18(4):383-391. doi: 10.1177/17474930221150349. Epub 2023 Jan 25.

Nagaratnam S, Harinesan N, Wijesinghe R, Wong-Doo N, Lyons A, Morris K, Triplett J. Painless progressive mononeuritis multiplex secondary to AML associated neuroleukemiosis. J Neuroimmunol. 2023 Apr 15;377:578061. doi: 10.1016/j.jneuroim.2023.578061. Epub 2023 Mar 5.

Narayan SW, Gad F, Chong J, Chen VM, Patanwala AE. Preventability of venous thromboembolism in hospitalised patients. Intern Med J. 2023 Apr;53(4):577-583. doi: 10.1111/imj.15600. Epub 2022 Aug 13.

Nastoupil LJ, Song Y, Sehn LH, Sarkozy C, Zinzani PL, Salar A, Zhang J, Huang S, Wang J, Delarue R, Trotman J. MAHOGANY: A Phase 3 Trial of Zanubrutinib Plus Anti-CD20 Antibodies vs Lenalidomide Plus Rituximab in Patients With Relapsed or Refractory Follicular or Marginal Zone Lymphoma. Journal of Clinical Oncology. 2023 May 31; 41(16). https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS7590

Nguyen J, Wellard C, Chung E, Cheah CY, Dickinson M, Doo NW, Keane C, Talaulikar D, Berkahn L, Morgan S, Hamad N, Cochrane T, Johnston AM, Forsyth C, Opat S, Barraclough A, Mutsando H, Ratnasingam S, Giri P, Wood EM, McQuilten ZK, Hawkes EA; Lymphoma and Related Diseases Registry investigators. Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. Eur J Haematol. 2023 Apr;110(4):386-395. doi: 10.1111/ejh.13915. Epub 2022 Dec 28.

Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Sabatelli L, Waltl EE, Winderlich M, Sporchia A, Kurukulasuriya NC, Cordoba R, Hess G, Salles G. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. Ann Hematol. 2023 Jul;102(7):1773-1787. doi: 10.1007/s00277-023-05196-4. Epub 2023 May 12. Erratum in: Ann Hematol. 2023 Sep;102(9):2643-2644.

Odutola MK, van Leeuwen MT, Bassett JK, Bruinsma F, Turner J, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Roncolato F, Opat SS, Lindeman R, Tiley C, Trotman J, Verner E, Harvey M, Underhill CR, Benke G, Giles GG, Vajdic CM. Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study. Front Nutr. 2023 Jan 4;9:1048301. doi: 10.3389/fnut.2022.1048301.

Odutola MK, van Leeuwen MT, Bruinsma FJ, Benke G, Turner MC, Trotman J, Turner J, Seymour JF, Prince HM, Milliken ST, Tiley C, Hertzberg M, Roncolato F, Opat S, Lindeman R, Verner E, Underhill CR, Cardis E, Giles G, Vajdic CM. Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case-control study. Occup Environ Med. 2023 Oct;80(10):599-602. doi: 10.1136/oemed-2023-108949. Epub 2023 Sep 18.

Opat S, Tedeschi A, Hu B, Linton K, Mckay P, Leitch S, Jin J, Sun M, Sobieraj-Teague M, Luigi Zinzani P, Browett P, Thieblemont C, Marina Liberati A, Bachy E, Cavallo F, Costello R, Iyengar S, Marasca R, Mociková H, Seok Kim J, Talaulikar D, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Long-Term Efficacy And Safety Of Zanubrutinib (Zanu) In Patients (Pts) With Relapsed/Refractory (R/R) Marginal Zone Lymphoma (Mzl): Final Analysis Of The Magnolia (Bgb-3111-214) Trial. Hemasphere. 2023 Aug 8; 7(Suppl ):e77003b0. https://doi.org/10.1097/01.HS9.0000971232.77003.b0

Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Leitch S, Coleman M, Zinzani PL, Jin J, Sun M, Sobieraj-Teague M, Browett P, Ke X, Thieblemont C, Ardeshna K, Bijou F, Walker P, Hawkes EA, Ho SJ, Zhou K, Liang Z, Xu J, Tankersley C, Delarue R, Co M, Trotman J. Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study. Blood Adv. 2023 Nov 28;7(22):6801-6811. doi: 10.1182/bloodadvances.2023010668.

Pennings GJ, Reddel CJ, Chen VM, Gnanenthiran SR, Kritharides L. Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease. Front Cardiovasc Med. 2023 Jan 19;9:1104744. doi: 10.3389/fcvm.2022.1104744.

Perram J, Purtill D, Bajel A, Butler J, O'Brien T, Teh B, Gilroy N, Ho PJ, Doocey R, Hills T, Perera T, Douglas G, Ramachandran S, Chee L, Trotman J, Weinkove R, Keogh S, Fraser C, Cochrane T, Watson AM, Diamond P, Latimer M, Irving I, Blyth E, Cheah C, Cole T, Milliken S, Yang H, Greenwood M, Bardy P, Kennedy G, Larsen S, Conyers R, Hamad N. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell. Intern Med J. 2023 Jan;53(1):119-125. doi: 10.1111/imj.15978.

Phillips EH, Kirkwood AA, Hague C, Vestbo J, Federico M, D'Amore F, Fossa A, Trotman J, Berkahn L, Molin DL, Luminari S, Barrington SF, Johnson P, Radford J. Bleomycin Affects Lung Function for at Least 5 Years after Treatment for Hodgkin Lymphoma - Data from the International, Randomised Phase 3 Rathl Trial. Blood. 2023 Nov 28; 142(1): 612. https://doi.org/10.1182/blood-2023-185818

Phillips K, Rijal S, Smyth L, Handunnetti S, Ngo C, Verner E, Trotman J, Agrawal S, Tatarczuch M, Tam C, Man SM. Impact of btki use in haematologic malignancies on inflammatory response signatures. International journal of laboratory hematology. International Journal of Laboratory Hematology. 2023 Jan 1; 4: 136-136. https://doi.org/10.1111/ijlh.14006

Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, Estell J, Delforge M, Offner F, Twomey P, Choeurng V, Li J, Hendricks R, Ruppert SM, Sumiyoshi T, Miller K, Cho E, Schjesvold F. Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma. Clin Hematol Int. 2023 Mar;5(1):43-51. doi: 10.1007/s44228-022-00023-5. Epub 2023 Jan 19.

Rankin K, Hastak P, Wong A, Sasson SC, Beaton B, Yeola A, Warden A, Turville S, Kelleher AD, Brilot F, Trotman J. Immune response to COVID-19 vaccination in patients with Waldenström macroglobulinaemia who pause their BTKi therapy. EJHaem. 2023 Jun 21;4(3):728-732. doi: 10.1002/jha2.724.

Reardon B, Smith S, Van Der Linde R, Sasson SC. Use of anti-JOVI. 1 antibodies to detect clonal T cell populations: implementation into a diagnostic flow cytometry laboratory and correlation with clinical findings. Pathology. 2023 Feb 1;55(1):S23. https://doi.org/10.1016/j.pathol.2022.12.077

Ricard F, Barrington S, Korn R, Brueggenwerth G, Trotman J, Cheson B, Salles G, Schwartz L, Goldmacher G, Jarecha R, Narang J, Broussais F, Galette P, Liu M, Bajpai S, Perlman E, Gillis J, Smalberg I, Terve P, Zahlmann G, Schmid A. Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical). J Nucl Med. 2023 Feb;64(2):239-243. doi: 10.2967/jnumed.122.264124. Epub 2022 Jul 14.

Ricard F, Cheson B, Barrington S, Trotman J, Schmid A, Brueggenwerth G, Salles G, Schwartz L, Goldmacher G, Jarecha R, Narang J, Broussais F, Galette P, Liu M, Bajpai S, Perlman E, Gillis J, Smalberg I, Terve P, Zahlmann G, Korn R. Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical). J Nucl Med. 2023 Jan;64(1):102-108. doi: 10.2967/jnumed.122.264106. Epub 2022 Jul 14.

Rijal S, Lim JH, Smyth L, Coombes C, Jain S, Saxena K, Trotman J, Verner E, Gandhi MK, Gandhi K, Talaulikar D. Analysis of the genetic landscape in elderly diffuse large b cell lymphoma aged>= 75 years identifies new targetable mutations. International Journal of Laboratory Hematology. 2023 Jan 01; 45: 148-148. https://doi.org/10.1111/ijlh.14006

Ross DM, Liang HPH, Iqra Z, Whittaker S, Tan CW, Dale BJ, Chen VM. Platelets from patients with myeloproliferative neoplasms have increased numbers of mitochondria that are hypersensitive to depolarization by thrombin. Sci Rep. 2023 Jun 6;13(1):9172. doi: 10.1038/s41598-023-36266-2.

Santoro A, Johnson NA, Savage KJ, Avigdor A, Bazargan A, Borchmann P, Gasiorowski R, Gregory GP, Herishanu Y, Madan S, Minuk L, Musuraca G, Marceau West R, Pillai P, Marinello P, Zinzani PL. Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study. Blood. 2023 Nov 28; 142(1): 1725. https://doi.org/10.1182/blood-2023-182536

Sehn L, Sarkozy C, Song Y, Salar A, Trotman J, Zinzani PL, Zhang J, Zhang W, Fustier P, Delarue R, Nastoupil L. MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 versus lenalidomide plus rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma. Hematological Oncology. 2023 Jun; 41:168-170. https://doi.org/10.1002/hon.3163_T04

Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia. Semin Thromb Hemost. 2023 Jul;49(5):444-452. doi: 10.1055/s-0043-1761269. Epub 2023 Jan 27.

Seymour JF, Cheah CY, Parrondo R, Thompson MC, Stevens DA, Lasica M, Wang ML, Kumar A, Trotman J, Alwan M, Ding W, By K, Tariq B, Chen X, Fabre S, Paik J, Agarwal A, Tam CS. First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101). Blood. 2023 Nov 28; 142(1): 4401. https://doi.org/10.1182/blood-2023-180109

Silvestre AS, Trotman J, Sarkozy C, Song Y, Sehn LH, Nastoupil LJ, Zhang W, Fustier P, Delarue R, Zinzani. PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA. HemaSphere. 2023 Aug;7(Suppl). e8253193. https://doi.org/10.1097/01.HS9.0000975836.58931.97

Talaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Gibbs S, Ling S, Ward C, Augustson BM, Trotman J, Harrison SJ, Tam CS; Medical and Scientific Advisory Group, Myeloma Australia. Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 2023 Apr;53(4):599-609. doi: 10.1111/imj.15980. Epub 2023 Apr 5.

Tam C, Anderson MA, Lasica M, Verner E, Opat SS, Ma S, Weinkove R, Cordoba R, Soumerai J, Chia P, Leitch S, Hilger J, Fang Y, Simpson D, Guo H, Cheah CY. Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study. Blood. 2023 Nov 02; 142(1): 327. https://doi.org/10.1182/blood-2023-179541

Tam C, Shadman M, Sharman J, Cull G, Phillips T, Trotman J, Cohen A, Allewelt H, Crescenzo R, Delarue R, Zhang H, Tariq B, Sahasranaman S, Ou YS, Flinn IW. PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES. HemaSphere. 2023 Aug;7(Suppl). e70124b5. https://doi.org/10.1097/01.HS9.0000974528.70124.b5

Tam CS, Trotman J, Opat S, Stern JC, Allewelt H, By K, Novotny W, Huang J, Tedeschi A. Zanubrutinib for the treatment of relapsed/refractory hairy cell leukemia. Blood Adv. 2023 Jun 27;7(12):2884-2887. doi: 10.1182/bloodadvances.2022008990.

Tariq B, Ou YC, Stern JC, Mundra V, Wong Doo N, Walker P, Lewis KL, Lin C, Novotny W, Sahasranaman S, Opat S. A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma. 2023 Feb;64(2):329-338. doi: 10.1080/10428194.2022.2150820. Epub 2022 Dec 8.

Tatarczuch M, Waltham M, Shortt J, Polekhina G, Hawkes EA, Ho SJ, Trotman J, Brasacchio D, Co M, Li J, Ramakrishnan V, Dunne K, Opat SS, Gregory GP. Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma. Blood Adv. 2023 Jul 25;7(14):3531-3539. doi: 10.1182/bloodadvances.2022009412.

Tedeschi A, Cheah CY, Opat SS, Verner E, Magnano L, Epperla N, Hilger J, Fang Y, Simpson D, Guo H, Anderson MA. Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study. Blood. 2023 Nov 02; 142(1): 3032. https://doi.org/10.1182/blood-2023-178841

Tedeschi A, Tam C, Owen R, Buske C, Leblond V, Dimopoulos MA, García-Sanz R, Castillo J, Trotman J, Treon S, Yang K, Tang B, Allewelt H, Patel S, Chan W, Cohen A, Schneider JY, Barnes Gisoo. P1679: Health-Related Quality Of Life In Patients (Pts) With Waldenström Macroglobulinemia (Wm) Treated With Zanubrutinib (Zanu) Vs Ibrutinib (Ibr): Results From The Phase 3 Aspen Trial Long-Term Follow-Up. HemaSphere. 2023 Aug 1; 7(S3):e27391ea. https://doi.org/10.1097/01.HS9.0000973588.27391.ea

Terpos E, Branagan AR, García-Sanz R, Trotman J, Greenberger LM, Stephens DM, Morel P, Kimby E, Frustaci AM, Hatjiharissi E, San-Miguel J, Dimopoulos MA, Treon SP, Leblond V. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management. Semin Hematol. 2023 Mar;60(2):107-112. doi: 10.1053/j.seminhematol.2023.03.004. Epub 2023 Mar 29.

Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings M, Lugtenburg PJ. Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247. doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.

Tobin JWD, Chowdhury R, Salvaris R, Griffin A, Chikatamarla V, Goh A, Tong TH, Birks C, Jain S, Goodall E, Sirdesai S, Trevis T, Elizabeth S, Chen Y, Black H, Broadby G, Li L, Gutta N, Morris KL, Cochrane T, Hapgood G. The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival. Blood. 2023 Nov 28; 142(1): 1671. https://doi.org/10.1182/blood-2023-185879

Tohidi-Esfahani I, Trotman J. Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more. Br J Haematol. 2023 Jun;201(5):807-808. doi: 10.1111/bjh.18664. Epub 2023 Jan 30.

Tohidi-Esfahani I, Xing Y, Venturelli V, Gavriilaki E, Kang X, Isenberg D, Cohen H, Efthymiou M. Complement Activation Is Increased in Antiphospholipid Syndrome-Related Ischemic Stroke with Higher Risk Features. Blood. 2023 Nov 28; 142(2): 3943. https://doi.org/10.1182/blood-2023-182287

Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R. Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. Hemasphere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919.

Tran HA, Deng L, Wood N, Choi P, Singleton S, Clarke L, Khanlari S, Maitland-Scott I, Bird R, Brown S, Manoharan B, Tan CW, Gold M, Hissaria P, Melody S, Chunilal S SD, Buttery J, Clothier H, Crawford NW, Phuong L, Pepperell D, Effler P, Parker C, Carter N, Macartney K, McStea M, Miller T, Nissen M, Larter C, Kay E, Chen VM. The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study. Lancet Reg Health West Pac. 2023 Sep 4;40:100894. doi: 10.1016/j.lanwpc.2023.100894.

Trotman J, LaCasce A, Osborne W, Steiner A, Hawkes E, Casulo C; Women in Lymphoma Steering Committee. Women in Lymphoma: A 4-year journey in promoting gender equity. Hematol Oncol. 2023 May 25. doi: 10.1002/hon.3183. Epub ahead of print.

Trotman J, Presgrave P, Carradice DP, Lenton DS, Gandhi MK, Cochrane T, Badoux X, Carlson J, Nkhoma G, Butcher B, Nikpour A, Fulham M, Johnston AM. Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. Hemasphere. 2023 Feb 21;7(3):e836. doi: 10.1097/HS9.0000000000000836.

Trotman J, Zinzani PL, Mayer J, Flowers C, Bijou F, Oliveira AC, Bouabdallah K, Johnson R, Garcia-Sancho AM, Pulla MP, Trneny M. P1080: Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the rosewood study. HemaSphere. 2023 Aug;7(Suppl). e2687131. https://doi.org/10.1097/01.HS9.0000971216.26871.31

Trotman J, Zinzani PL, Mayer J, Flowers CR, Bijou F, de Oliveira AC, Bouabdallah K, Johnson R, Garcia-Sancho AM, Pulla MP, Trněný M, Tilly H, Wojiech J, Ivanova E, Kim P, Greenbaum A, Huang S, Delarue R, Auer R. Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study. Hematological Oncology. 2023 Jun 9; 41(S2):119-121. https://doi.org/10.1002/hon.3163_81

Trotman J, Zinzani PL, Song Y, Delarue R, Barnes G, Kim P, Ivanova E, Tang B, Mayer J, De Oliveira AC, Assouline S, Flowers CR. Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated with Zanubrutinib+ Obinutuzumab Versus Obinutuzumab Monotherapy: The Rosewood Trial. Blood. 2023 Nov 28; 142(1): 1674. https://doi.org/10.1182/blood-2023-181195

van der Linde R, Smith S, Brown DA, Sasson SC, Tegg E. Measurable residual disease in adult acute myeloid leukaemia: evaluation of a multidimensional 'radar' flow cytometric plot analysis method. Pathology. 2023 Apr;55(3):383-390. doi: 10.1016/j.pathol.2022.10.007. Epub 2022 Dec 30.

Verner E, Johnston A, Pati N, Hawkes E, Lee HP, Cochrane T, Cheah CY, Filshie R, Purtill D, Sia H, Enjeti AK, Brown C, Murphy N, Curnow J, Lee K, Gandhi M, Butcher B, Trotman J. P1127: Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: a phase ii study of ibrutinib, rituximab and mini-chop in very elderly patients with newly diagnosed BLBCL. HemaSphere. 2023 Aug;7(Suppl). e129974b https://doi.org/10.1097/01.hs9.0000971404.12997.4b

Wilson MR, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Lees C, Fox C, Preston G, Ahearne M, Strüßmann T, Clavert A, Rusconi C, Ku M, Khwaja J, Narkhede M, Lewis K, Durot E, Smith J, Renaud L, Ferreri AJM, El-Galaly T, Cwynarski K, McKay P, Eyre TA. Dosage of high-dose methotrexate as CNS prophylaxis in DLBCL: A detailed analysis of toxicity and impact on CNS relapse. Am J Hematol. 2024 Feb;99(2):E46-E50. doi: 10.1002/ajh.27167. Epub 2023 Nov 30.

Wood EM, Chai KL, Reynolds J, Griffiths J, Beaton B, Callum J, Crassini KR, Crispin PJ, Fanning L, Gilbertson M, Grigg AP, Hawkes EA, Morrissey CO, Mulligan SP, Opat SS, Paterson DL, Petrie D, Roberts JA, Ryan EG, Spencer A,McQuilten ZK. Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain. Blood. 2023 Nov 28; 142(1): 1295. https://doi.org/10.1182/blood-2023-181541

Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong A, Shortt J, Burbury K, Chee L, Viiala N, Cunningham I, Ross DM, D'Souza AB, Wright M, Harrup RA, Forsyth C, Filshie R, Browett PJ, Lane S, Grove C. Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study. Blood. 2023 Nov 02; 142(1): 865. https://doi.org/10.1182/blood-2023-172583

Yeung J, Dix CHK, Ritchie AG, Kow M, Chen VMY. Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study. Intern Med J. 2023 Jan;53(1):68-73. doi: 10.1111/imj.15010. Epub 2022 Dec 5.

Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martín García-Sancho A, Provencio Pulla M, Trněný M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J. ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. J Clin Oncol. 2023 Nov 20;41(33):5107-5117. doi: 10.1200/JCO.23.00775. Epub 2023 Jul 28.

Zlamal J, Aliotta A, Alberio L, Chen V, Bakchoul T; SSC Platelet Immunology of the ISTH. Diagnostic value of antibody-induced procoagulant platelets in heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost. 2024 Mar;22(3):860-868. doi: 10.1016/j.jtha.2023.11.019. Epub 2023 Dec 7.

2022

Adattini JA, Gross AS, Wong Doo N, McLachlan AJ. Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience. Pharmacol Res Perspect. 2022 Oct;10(5):e01005. doi: 10.1002/prp2.1005.

Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue M-H, de Level L, Meignan M, Li J, Morschhauser F, Delarue R. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). Journal of Clinical Oncology, 2022 January; 40 (3): 242-251. doi: https://doi.org/10.1200/JCO.21.01815

Barrington SF, Mir F, El-Galaly TC, Knapp A, Nielsen TG, Sahin D, Wenger M, Kostakoglu L, Trotman J, Meignan M. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study. J Nucl Med. 2022 Aug;63(8):1149-1154. doi: 10.2967/jnumed.121.262869.

Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF Jr, Gabbas A, Ghesquières H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. 2022 Dec;36(12):2835-2844. doi: 10.1038/s41375-022-01711-0.

Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized phase III iNNOVATE study. Journal of Clinical Oncology, 2022 Jan 1; 40 (1): 52-62(11); doi: https://doi.org/10.1200/JCO.21.00838

Cartron G, Trotman J. Time for an individualized approach to first-line management of follicular lymphoma. Haematologica. 2022 Jan 1; 107(1): 7-18. doi: 10.3324/haematol.2021.278766.

Chen V, Akhtar S, Zheng C, Kumaresan V, Nouri K. Assessment of Changes in Diversity in Dermatology Clinical Trials Between 2010-2015 and 2015-2020: A Systematic Review. JAMA Dermatol. 2022 Mar 1;158(3):288-292. doi: 10.1001/jamadermatol.2021.5596.

Chen V, Strazzulla L, Asbeck SM, Bellodi Schmidt F. Etiology, management, and outcomes of pediatric telogen effluvium: A single-center study in the United States. Pediatr Dermatol. 2023 Jan;40(1):120-124. doi: 10.1111/pde.15154.

Choi PY, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VMY, Chong BH, Curnow J, Pepperell D, Bird R. Immune thrombocytopenia following vaccination during the COVID-19 pandemic. Haematologica. 2022 May 1;107(5):1193-1196. doi: 10.3324/haematol.2021.279442.

Connor D, Rabbolini D, Morel-Kopp MC, Fixter K, Donikian D, Kondo M, Chan O, Jarvis S, Chen W, Brighton T, Chen V, Ward C, Joseph J. The utility of flow cytometric platelet forward scatter as an alternative to mean platelet volume. Platelets. 2022 Nov 17;33(8):1139-1145. doi: 10.1080/09537104.2022.2052035. Epub 2022 Mar 22.

Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 Mar;196(5):1209-1218. doi: 10.1111/bjh.17994.

de Leval L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, Dogan A, Fitzgibbon J, Horwitz SM, Melnick AM, Morice WG, Morin RD, Nadel B, Pileri SA, Rosenquist R, Rossi D, Salaverria I, Steidl C, Treon SP, Zelenetz AD, Advani RH, Allen CE, Ansell SM, Chan WC, Cook JR, Cook LB, d'Amore F, Dirnhofer S, Dreyling M, Dunleavy K, Feldman AL, Fend F, Gaulard P, Ghia P, Gribben JG, Hermine O, Hodson DJ, Hsi ED, Inghirami G, Jaffe ES, Karube K, Kataoka K, Klapper W, Kim WS, King RL, Ko YH, LaCasce AS, Lenz G, Martin-Subero JI, Piris MA, Pittaluga S, Pasqualucci L, Quintanilla-Martinez L, Rodig SJ, Rosenwald A, Salles GA, San-Miguel J, Savage KJ, Sehn LH, Semenzato G, Staudt LM, Swerdlow SH, Tam CS, Trotman J, Vose JM, Weigert O, Wilson WH, Winter JN, Wu CJ, Zinzani PL, Zucca E, Bagg A, Scott DW. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022 Nov 24;140(21):2193-2227. doi: 10.1182/blood.2022015854.

Dix C, McFadyen J, Huang A, Chunilal S, Chen V, Tran H. Understanding vaccine-induced thrombotic thrombocytopenia (VITT). Intern Med J. 2022 May;52(5):717-723. doi: 10.1111/imj.15783.

Ellis ML, Alwis I, Smythe R, Yuan Y, Jackson SP. Megakaryocyte buds are distinct from microvesicles and likely to represent platelet precursors. Blood Adv. 2022 Nov 10:bloodadvances.2022008850. doi: 10.1182/bloodadvances.2022008850.

Favaloro EJ, Clifford J, Leitinger E, Parker M, Sung P, Chunilal S, Tran H, Kershaw G, Fu S, Passam F, Ahuja M, Ho SJ, Duncan E, Yacoub O, Tan CW, Kaminskis L, Modica N, Pepperell D, Ballard L, Clarke L, Lee CSM, Gardiner EE, Young-Ill Choi P, Tohidi-Esfahani I, Bird R, Brighton T, Chen VM. Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: A multicenter study comprising 1284 patients. J Thromb Haemost. 2022 Dec;20(12):2896-2908. doi: 10.1111/jth.15881.

Gasiorowski R, Forbes MK, Silver G, Krastev Y, Hamdorf B, Lewis B, Tisbury M, Cole-Sinclair M, Lanphear BP, Klein RA, Holmes N, Taylor MP. Effect of Plasma and Blood Donations on Levels of Perfluoroalkyl and Polyfluoroalkyl Substances in Firefighters in Australia: A Randomized Clinical Trial. JAMA Netw Open. 2022 Apr 1;5(4):e226257. doi: 10.1001/jamanetworkopen.2022.6257.

Gasiorowski R, Trotman J. CAR-T for follicular lymphoma: are we good to go? Blood. 2022 Aug 25;140(8):799-800. doi: 10.1182/blood.2022017279.

Gnanenthiran SR, Pennings GJ, Reddel CJ, Campbell H, Kockx M, Hamilton JR, Chen VM, Kritharides L. Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance. Arterioscler Thromb Vasc Biol. 2022 Aug;42(8):960-972. doi: 10.1161/ATVBAHA.120.316772.

Harrop S, Di Ciaccio P, Doo NW, Cochrane T, Campbell BA, Hamad N, Dickinson M, Van Der Weyden C, Prince HM. The gamma delta lymphomas: an Australian multi-centre case series. Annals of Lymphoma, 2022;6:3. doi: 10.21037/aol-21-41.

Islam S, Cullen T, Sumpton D, Damodaran A, Heath D, Bosco A, Wong Doo N, Kidson-Gerber G, Cheong A, Lawford R, Walsh R, Sammel A. VEXAS syndrome: lessons learnt from an early Australian case series. IMJ. 2022 Apr;52(4):658-662. doi: 10.1111/imj.15742.

Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D'Rozario J, Taylor K, Estell J, Norton S, Kemp R, Mitchell AJ, Reynolds J, Kennedy N, Quach H, Spencer A. Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica. 2022 Jan 1; 107(1):321-325. doi: 10.3324/haematol.2021.278655.

Kershaw G, Dix C, Chen VM, Cai N, Khoo TL. Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement. Pathology. 2022 Oct;54(6):755-762. doi: 10.1016/j.pathol.2022.02.006.

Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297.

Lee CSM, Liang HPH, Connor DE, Dey A, Tohidi-Esfahani I, Campbell H, Whittaker S, Capraro D, Favaloro EJ, Donikian D, Kondo M, Hicks SM, Choi PY, Gardiner EE, Clarke LJ, Tran H, Passam FH, Brighton TA, Chen VM. A novel flow cytometry procoagulant assay for diagnosis of vaccine-induced immune thrombotic thrombocytopenia.Blood Adv. 2022 Jun 14;6(11):3494-3506. doi: 10.1182/bloodadvances.2021006698.

Lee CSM, Selvadurai MV, Pasalic L, Yeung J, Konda M, Kershaw GW, Favaloro EJ, Chen VM. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia. J Thromb Haemost. 2022 Apr;20(4):975-988. doi: 10.1111/jth.15650. Epub 2022 Feb 7.

Li EW, Krishnaswamy M, El-Wahsh S, Balgobind S, Trotman J, Tan I, Hardy TA. Paraneoplastic primary CNS angiitis secondary to nodular lymphocyte predominant Hodgkin lymphoma. Pathology. 2022 Oct 29:S0031-3025(22)00278-1. doi: 10.1016/j.pathol.2022.08.012.

lTalaulikar D, Joshua D, Ho PJ, Gibson J, Quach H, Gibbs S, Ling S, Ward C, Augustson B, Trotman J, Harrison SJ, Tam CS. Treatment of Patients with Waldenström Macroglobulinaemia: Clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Medical and Scientific Advisory Group, Myeloma Australia. Intern Med J. 2022 Nov 28. doi: 10.1111/imj.15980.

Marks DI, Kirkwood AA, Rowntree CJ, Aguiar M, Bailey KE, Beaton B, Cahalin P, Castleton AZ, Clifton-Hadley L, Copland M, Goldstone AH, Kelly R, Lawrie E, Lee S, McMillan AK, McMullin MF, Menne TF, Mitchell RJ, Moorman AV, Patel B, Patrick P, Smith P, Taussig D, Yallop D, Alapi KZ, Fielding AK. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial. Lancet Haematol. 2022 Apr;9(4):e262-e275. doi: 10.1016/S2352-3026(22)00038-2.

Nath CE, Grigg A, Rosser SPA, Estell J, Newman E, Tiley C, Ramanathan S, Ho SJ, Larsen S, Gibson J, Presgrave P, Shaw PJ, Trotman J. Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma. Eur J Clin Pharmacol. 2022 Dec;78(12):1911-1921. doi: 10.1007/s00228-022-03396-x.

Nowakowski GS, Yoon DH, Peters A, Mondello P, Joffe E, Fleury I, Greil R, Ku M, Marks R, Kim K, Zinzani PL, Trotman J, Huang D, Waltl EE, Winderlich M, Kurukulasuriya NC, Ambarkhane S, Hess G, Salles G. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clin Cancer Res. 2022 Sep 15;28(18):4003-4017. doi: 10.1158/1078-0432.CCR-21-3648.

Odutola MK, van Leeuwen MT, Turner J, Bruinsma F, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Trotman J, Opat SS, Lindeman R, Roncolato F, Verner E, Harvey M, Tiley C, Underhill CR, Benke G, Giles GG, Vajdic CM. Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study. Cancer Epidemiol. 2022 Oct;80:102241. doi: 10.1016/j.canep.2022.102241.

Odutola MK, van Leeuwen MT, Turner J, Bruinsma F, Seymour JF, Prince HM, Milliken ST, Trotman J, Verner E, Tiley C, Roncolato F, Underhill CR, Opat SS, Harvey M, Hertzberg M, Benke G, Giles GG, Vajdic CM. Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. Cancers (Basel). 2022 May 30;14(11):2710. doi: 10.3390/cancers14112710.

Pastar I, Balukoff NC, Marjanovic J, Chen VY, Stone RC, Tomic-Canic M. Molecular Pathophysiology of Chronic Wounds: Current State and Future Directions. Cold Spring Harb Perspect Biol. 2022 Sep 19:a041243. doi: 10.1101/cshperspect.a041243.

Pennings GJ, Reddel CJ, Traini M, Lam M, Kockx M, Chen VM, Kritharides L. Rapid Release of Interleukin-1β from Human Platelets Is Independent of NLRP3 and Caspase. Thromb Haemost. 2022 Apr;122(4):517-528. doi: 10.1055/s-0041-1731288.

Phillips T, Chan H, Tam CS, Tedeschi A, Johnston P, Oh SY, Opat S, Eom HS, Allewelt H, Stern JC, Tan Z, Novotny W, Huang J, Trotman J. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2022 Jun 14;6(11):3472-3479. doi: 10.1182/bloodadvances.2021006083.

Rabbolini D, Liang HPH, Morel-Kopp MC, Connor D, Whittaker S, Dunkley S, Donikian D, Kondo M, Chen W, Stevenson WS, Campbell H, Joseph J, Ward C, Brighton T, Chen VM; Sydney Platelet Group. Building platelet phenotypes: Diaphanous-related formin 1 (DIAPH1)-related disorder. Platelets. 2022 Apr 3;33(3):432-442. doi: 10.1080/09537104.2021.1937593.

Rankin, K.; Beaton, B.; Sasson, S.; Raedemaecker, J.; Wong, A.; Hastak, P.; Phetsouphanh, C.; Warden, A.; Patel, M.; Klemm, V.; Munier, C. M. L.; Carey Hoppe, A.; Tea, F.; Pillay, A.; Ospina, A.; Aggarwal, A.; Lavee, O.; Caterson, I. D.; Turville, S.; Kelleher, A. D.; Brilot, F.; Trotman, J. Efficacy of a 3rd covid vaccine, including during a btki pause, in individuals with waldenström macroglobulinemia and follicular lymphoma. HemaSphere 6():p 1958-1959, June 2022. | DOI: 10.1097/01.HS9.0000851180.32970.18

Reddel CJ, Pennings GJ, Chen VM, Gnanenthiran S, Kritharides L. Colchicine as a Modulator of Platelet Function: A Systematic Review. Semin Thromb Hemost. 2022 Jul;48(5):552-567. doi: 10.1055/s-0042-1749660.

Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trněný M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):1031-1043. doi: 10.1016/S1470-2045(22)00293-5.

Tam CS, Dimopoulos M, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen R, Song Y, Xu W, Zhu J, Li J, Qiu L, D'Sa S, Jurczak W, Cull G, Marlton P, Gottlieb D, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H, Zhu H, Chan WY, Cohen A, Novotny W, Huang J, Tedeschi A. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2022 Feb 22;6(4):1296-1308. doi: 10.1182/bloodadvances.2021005621.

Trotman J. Lymphoma and Related Diseases Registry Investigators. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Med Res Methodol. 2022 Oct 10;22(1):266. doi: 10.1186/s12874-022-01728-0.

Trotman J, Pettitt AR. Is it time for PET-guided therapy in follicular lymphoma? Blood. 2022 Mar 17;139(11):1631-1641. doi: 10.1182/blood.2020008243.

Trotman J. Key points from the SHINE trial in mantle cell lymphoma. Clin Adv Hematol Oncol. 2022 Nov;20(11):652-654.

Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernández-Rivas JÁ, Hong X, Kim SJ, Lewis D, Mishima Y, Özcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817.

Wight J, Hamad N, Campbell BA, Ku M, Lee K, Rose H, Armytage T, Latimer M, Lee HP, Lee ST, Dickinson M, Khor R, Verner E. Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Intern Med J. 2022 Sep;52(9):1609-1623. doi: 10.1111/imj.15533.

Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne M, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, McIlroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüßmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood. 2022 Apr 21;139(16):2499-2511. doi: 10.1182/blood.2021014506.

Wong J, Gruber E, Maher B, Waltham M, Sabouri-Thompson Z, Jong I, Luong Q, Levy S, Kumar B, Brasacchio D, Jia W, So J, Skinner H, Lewis A, Hogg SJ, Vervoort S, DiCorleto C, Uhe M, Gamgee J, Opat S, Gregory GP, Polekhina G, Reynolds J, Hawkes EA, Kailainathan G, Gasiorowski R, Kats LM, Shortt J. Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Leukemia. 2022 Jun;36(6):1654-1665. doi: 10.1038/s41375-022-01571-8.

Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J. Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Adv Ther. 2022 Sep;39(9):4250-4265. doi: 10.1007/s12325-022-02238-7.

Yeung D, Grigg A, Shanmuganathan N, Soltenbeck A, White D, Branford S, Viiala N, Rowlings P, Mills A, Shortt J, C Tiley, Ross D, Kipp D, Harrup R, Cunningham I, Kwan J, Eek R, Mutsando H, Tan K-S, Burbury K, Wright M, Hughes T. Proactive dasatinib dose reduction in the allg cml 12 direct study based on trough levels minimise toxicity and preserve efficacy. HemaSphere 6():p 615-616, June 2022. | DOI: 10.1097/01.HS9.0000845764.61186.15

2021

Barrington SF, Mir F, El-Galaly TC, Knapp A, Nielsen TG, Sahin D, Wenger M, Kostakoglu L, Trotman J, Meignan MFollicular lymphoma treated with first-line immunochemotherapy: a review of PET-CT in patients who did not achieve CMR in the GALLIUM study. J Nucl Med. 2021 Dec 2:jnumed.121.262869. doi: 10.2967/jnumed.121.262869.

Barrington SF, Trotman J. The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma. Lancet Haematol. 2021 Jan 8 https://doi.org/10.1016/s2352-3026(20)30365-3;

Barrow TM, Wong Doo N, Milne RL, Giles GG, Willmore E, Strathdee G, Byun HM. Analysis of retrotransposon subfamily DNA methylation reveals novel early epigenetic changes in chronic lymphocytic leukaemia. Haematologica. 2021 Jan 1 https://doi.org/10.3324/haematol.2019.228478

Bernard S, Ghesquieres H, Casasnovas R, Griolet S, da Silva MG, Feugier P, Morschhauser F, Trotman J, Renaud L, Greil L, García-Sancho A, Grosicki S, van Eygen K, Copie-Bergman C, Haioun C, Thieblemont C . Incidence of central nervous system relapses in patients with DLBCL treated with lenalidomide as maintenance after R-CHOP. Blood Adv (2021) 5 (15): 2965-2968. https://doi.org/10.1182/bloodadvances.2021004766.

Brendan Beaton, Sarah C Sasson, Katherine Rankin, Juliette Raedemaeker, Alexander Wong, Priyanka Hastak, Andrew Warden, Alberto Ospina Stella, Anupriya Aggarwal, Ian D Caterson, Chansavath Phetsouphanh, Stuart Turville, Anthony D Kelleher, Fabienne Brilot, Judith Trotman,Efficacy of Vaccine BNT162b2 (Pfizer-BioNTech) in Individuals with Waldenstrom's Macroglobulinemia and Follicular Lymphoma in Australia. Volume 138, Supplement 1, 2021, Page 816, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-149348.

Cartwright B, Bruce HM, Kershaw G, Cai N, Othman J, Gattas D, Robson JL, Hayes S, Alicajic H, Hines A, Whyte A, Chaikittisilpa N, Southwood TJ, Forrest P, Totaro RJ, Bannon PG, Dunkley S, Chen VM, Dennis M. Hemostasis, coagulation and thrombin in venoarterial and venovenous extracorporeal membrane oxygenation: the HECTIC study. Sci Rep. 2021 Apr 12 https://doi.org/10.1038/s41598-021-87026-z.

Chen V, Escandon Brehm J, Bellodi Schmidt F. Acute urticaria preceding other COVID-19-associated manifestations-A case report. Pediatr Dermatol. 2021 Mar https://doi.org/10.1111/pde.14505.

Chen V, Head HT. Australian New Zealand approach to diagnosis and management of vaccine induced immune thrombosis and thrombocytopenia. The Medical Journal of Australia. 2021 Jun 10:1.

Chen VM, Curnow JL, Tran HA, Choi PY. Australian and New Zealand approach to diagnosis and management of vaccine-induced immune thrombosis and thrombocytopenia. Med J Aust. 2021 Sep 20;215(6):245-249.e1. doi: 10.5694/mja2.51229. Epub 2021 Sep 6.

Choi PY, Hsu D, Tran HA, Tan CW, Enjeti A, Chen VMY, Chong BH, Curnow J, Pepperell D, Bird R. Immune thrombocytopenia following vaccination during the COVID-19 pandemic. Haematologica. 2021 Aug 26. doi: 10.3324/haematol.2021.279442. Online ahead of print.

Chong J, Curtain C, Gad F, Passam F, Soo G, Levy R, Dunkley S, Wong Doo N, Cunich M, Burke R, Chen V.Development and implementation of venous thromboembolism stewardship across a hospital network. Int J Med Inform. 2021 Nov;155:104575. doi: 10.1016/j.ijmedinf.2021.104575. Epub 2021 Sep 14.

Clothier HJ, Mesfin YM, Strange S, Buttery JP, Wark PA, MacIntyre CR, Bell S, Oliver B, Marks GB, Chen V, Curnow JL. Estimating background rates of hospital transfers and deaths in aged care facilities, following COVID-19 vaccination, Australia. The Medical Journal of Australia. 2021 Jun 16:1.

Cochrane T, Campbell BA, Gangatharan SA, Latimer M, Khor R, Christie DRH, Gilbertson M, Ratnasingam S, Palfreyman E, Lee HP, Trotman J, Hertzberg M, Dickinson M.Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Intern Med J. 2021 Dec;51(12):2119-2128. doi: 10.1111/imj.15503. Epub 2021 Nov 22.

Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS.Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2021 Dec 16. doi: 10.1111/bjh.17994. Online ahead of print.

Cumpston MS, Webb SA, Middleton P, Sharplin G, Green S,Best K, Bloomfield F, Cass A, Cohen P, Crengle S, Cullen L, Gantner D, Gaulke H, Ghersi D, Green S, Glasziou P, Harris-Brown T, Jan S, Johnson D, Keogh S, Levi C, Middleton P, Peake S, Scheppokat A, Scuffham P, Sharplin G, Shaw T, Story D, Teede H, Theisz, Trotman J, Webb S, Weller C, Woollett A, Zoungas S. Understanding implementability in clinical trials: a pragmatic review and concept map. Trials. 2021 Mar 26 https://doi.org/10.1186/s13063-021-05185-w;

Doo NW, Trotman J. 2?+?2 in the long term: informing a new standard of care in 2021 for early stage, unfavourable Hodgkin lymphoma. Lancet Haematol. 2021 Apr https://doi.org/10.1016/s2352-3026(21)00063-6

Dugué PA, Bassett JK, Wong EM, Joo JE, Li S, Yu C, Schmidt DF, Makalic E, Doo NW, Buchanan DD, Hodge AM. Biological aging measures based on blood DNA methylation and risk of cancer: a prospective study. JNCI cancer spectrum. 2021 Feb;5(1):pkaa109. https://doi.org/10.1093/jncics/pkaa109.

Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study, Emma Verner, Amanda Johnston, Nalini Pati, Eliza Hawkes, Hui-Peng Lee, Tara Cochrane, Chan-Yoon Cheah, Robin J Filshie, Duncan Purtill, Hanlon Sia, Anoop Kumar Enjeti, Christina Brown, Nicholas E. Murphy, Jennifer Curnow, Kenneth Lee, Mannu Walia, Belinda Butcher, Judith Trotman, Blood, Volume 138, Supplement 1, 2021, Page 304, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-149019.

Fleming, Shaun & Reynolds, John & Bajel, Ashish & Venn, Nicola & Kwan, John & Moore, John & Yeung, David & Pati, Nalini & Leahy, Michael & Nkyekyer, Joanna & Verner, Emma & Berkahn, Leanne & Sutton, Rosemary & Wei, Andrew & Greenwood, Matthew. (2021). Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study. Blood. 138. 1234-1234. 10.1182/blood-2021-151826.

Georgia Mills, John Moore, Edward Cliff, Chun Yew Fong, Sarah Mangalasseril, Campbell Tiley, Michael Gilbertson, Matthew Ku, Ali Bazargan, Michelle Bryson, Monique Menzies Wojtowicz, Nagendra Prasad Sungala, Ilona Cunningham, Catherine Tang, Nada Hamad, Promising Real World Survival Data in Adult-Onset Langerhans Cell Histiocytosis: An Australasian Lymphoma Alliance 20 Year Retrospective Study, Blood, Volume 138, Supplement 1, 2021, Page 2570, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-152131.

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Anthea Peters, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Dan Huang, Eva E. Waltl, Mark Winderlich, Sumeet Ambarkhane, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles. Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, Volume 138, Supplement 1, 2021, Page 183, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-148302

Hocking J, Chunilal SD, Chen V, Brighton T, Nguyen J, Tan J, Ting SBN and Tran H. The first known ChAdOx1 nCoV-19 vaccine-induced thrombotic thrombocytopenia in Australia. The Medical Journal of Australia. 2021;215(1):19.

Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710.

Hundertmark WJ, Lee M, Smith IA, Bang AHY, Chen V, Gately CK, Templer PH, Hutyra LR. Influence of landscape management practices on urban greenhouse gas budgets. Carbon Balance Manag. 2021 Jan 7 https://doi.org/10.1186/s13021-020-00160-5.

Ibrahim Tohidi-Esfahani, Andrew Warden, Elena Malunis, Peter Liburdi deNardis, Michelle Postek, Shirley D'Sa, Marie José Kersten, Sheeba K Thomas, M. Lia Palomba, Adam J. Olszewski, Newton Guerin, Clare Scott, Judith Trotman,Global Waldenström's Macroglobulinemia Patient-Derived Data Registry, Whimsical, Highlights Real-World Treatment Outcomes and COVID-19 Data. Blood, Volume 138, Supplement 1, 2021, Page 1343, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-147720.

Jacqueline S. Garcia, Andrew H. Wei, Meagan A. Jacoby, Chun Yew Fong, Uma Borate, Maria R. Baer, Ilona Cunningham, Olatoyosi Odenike, Joseph G. Jurcic, Daniel Nowak, Pierre Peterlin, Uwe Platzbecker, Diana Dunshee, Ying Zhou, David Hoffman, Yan Sun, Relja Popovic, Barrett Ainsworth, Kiran Naqvi, Steve Kye, Leah Hogdal, Guillermo Garcia-Manero, Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine, Blood, Volume 138, Supplement 1, 2021, Page 241, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-145613. 

Jacqueline Suen Garcia, Andrew Wei, Uma Borate, Chun Yew Fong, Maria R. Baer, Daniel Nowak, Pierre Peterlin, Joseph G. Jurcic, Meagan Jacoby, Uwe Platzbecker, Olatoyosi Odenike, Ilona Cunningham, Ying Zhou, David Hoffman, Kiran Naqvi, Steve Kye, and Guillermo Garcia-aneroComparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine. Journal of Clinical Oncology 2021 39:15_suppl, 7041-7041 DOI:10.1200/JCO.2021.39.15_suppl.7041

Judith Trotman, Peter Presgrave, Duncan P. Carradice, Douglas Stuart Lenton, Maher Gandhi, Tara Cochrane, Xavier Badoux, Gloria Nkhoma, Belinda Butcher, Michael Fulham, Anna Johnston. Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive after Treatment for Relapsed Follicular Lymphoma: Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. Volume 138, Supplement 1, 2021, Page 2428, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-146343.

Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. Eur J Cancer. 2021 May;148:411-421. PMID: 33794441 https://doi.org/10.1016/j.ejca.2021.01.054.

Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL; KEYNOTE-204 investigators. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021 Apr 22 https://doi.org/10.1016/s1470-2045(21)00005-x

McCaughan, G., Di Ciaccio, P., Ananda-Rajah, M., Gilroy, N., MacIntyre, R., Teh, B., Weinkove, R., Curnow, J., Szer, J., Enjeti, A.K., Ross, D.M., Mulligan, S., Trotman, J., Dickinson, M., Quach, H., Choi, P., Polizzotto, M.N., Tam, C.S., Ho, P.J., Ku, M., Gregory, G., Gangatharan, S., Hapgood, G., Cochrane, T., Cheah, C., Gibbs, S., Wei, A., Johnston, A., Greenwood, M., Prince, H.M., Latimer, M., Berkahn, L., Wight, J., Armytage, T. and Hamad, N. COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Intern Med J, 2021 June 02 https://doi.org/10.1111/imj.15247;

Merriman E, Chunilal S, Brighton T, Chen V, McRae S, Ockelford P, Curnow J, Tran H, Chong B, Smith M, Royle G, Crowther H, Slocombe A, Tran H. Two Weeks of Low Molecular Weight Heparin for Isolated Symptomatic Distal Vein Thrombosis (TWISTER study). Thromb Res. 2021 Sep 11;207:33-39. doi: 10.1016/j.thromres.2021.09.004. Online ahead of print.

Moore A, Machiela MJ, Machado M, Wang SS, Kane E, Slager SL, Zhou W, Carrington M, Lan Q, Milne RL, Birmann BM, Adami HO, Albanes D, Arslan AA, Becker N, Benavente Y, Bisanzi S, Boffetta P, Bracci PM, Brennan P, Brooks-Wilson AR, Canzian F, Caporaso N, Clavel J, Cocco P, Conde L, Cox DG, Cozen W, Curtin K, De Vivo I, de Sanjose S, Foretova L, Gapstur SM, Ghesquières H, Giles GG, Glenn M, Glimelius B, Gao C, Habermann TM, Hjalgrim H, Jackson RD, Liebow M, Link BK, Maynadie M, McKay J, Melbye M, Miligi L, Molina TJ, Monnereau A, Nieters A, North KE, Offit K, Patel AV, Piro S, Ravichandran V, Riboli E, Salles G, Severson RK, Skibola CF, Smedby KE, Southey MC, Spinelli JJ, Staines A, Stewart C, Teras LR, Tinker LF, Travis RC, Vajdic CM, Vermeulen RCH, Vijai J, Weiderpass E, Weinstein S, Doo NW, Zhang Y, Zheng T, Chanock SJ, Rothman N, Cerhan JR, Dean M, Camp NJ, Yeager M, Berndt SI. Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. J Transl Genet Genom. 2021;5:200-217. doi: 10.20517/jtgg.2021.08. Epub 2021 Jun 17.

Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, Salles GA, Trn?ný M, de Vos S, Mir F, Samineni D, Kim SY, Jiang Y, Punnoose E, Sinha A, Clark E, Spielewoy N, Humphrey K, Bazeos A, Zelenetz AD.A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021 Feb 4;137(5):600-609. doi: 10.1182/blood.2020006578.

Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, Johnson NA, Larouche JF, Lugtenburg PJ, Patti C, Salles GA, Trn?ný M, de Vos S, Mir F, Samineni D, Kim SY, Jiang Y, Punnoose E, Sinha A, Clark E, Spielewoy N, Humphrey K, Bazeos A, Zelenetz AD. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021 Feb 4; https://doi.org/10.1182/blood.2020006578

Narayan SW, Gad F, Chong J, Chen VM, Patanwala AE. Preventability of Venous Thromboembolism in Hospitalised Patients. Intern Med J. 2021 Nov 1. doi: 10.1111/imj.15600. Online ahead of print.

Nath K, Law SC, Sabdia MB, Gunawardana J,de Long LM, Sester D, Shanavas M, Tsang H, Tobin J.W.D, Halliday SJ, Hernandez A, Cross D, Bird RJ, Jain S, Keane C, Talaulikar D, Trotman J, Law P, Gandhi MK; Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Adv 2021; 5 (12): 2644-2649 22June2021. doi: https://doi.org/10.1182/bloodadvances.2020004051

Opat S, Tedeschi A, Linton K, McKay P, Hu B, Chan H, Jin J, Sobieraj-Teague M, Zinzani PL, Coleman M, Thieblemont C, Browett P, Ke X, Sun M, Marcus R, Portell CA, Ardeshna K, Bijou F, Walker P, Hawkes EA, Mapp S, Ho SJ, Talaulikar D, Zhou KS, Co M, Li X, Zhou W, Cappellini M, Tankersley C, Huang J, Trotman J.The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. Clin Cancer Res. 2021 Dec 1;27(23):6323-6332. doi: 10.1158/1078-0432.CCR-21-1704. Epub 2021 Sep 15.

Passam FH, Chen G, Chen VM, Qi M, Krilis SA, Giannakopoulos B. Βeta-2-glycoprotein I exerts antithrombotic function through its domain V in mice. J Autoimmun. 2022 Jan; 126:102747. doi: 10.1016/j.jaut.2021.102747. Epub 2021 Nov 15.

Pastar I, Marjanovic J, Stone RC, Chen V, Burgess JL, Mervis JS, Tomic-Canic M. Epigenetic regulation of cellular functions in wound healing. Exp Dermatol. 2021 Mar 10 https://doi.org/10.1111/exd.14325.

Pennings G, Reddel C, Traini M, Lam M, Kockx M, Chen V, Kritharides L. Rapid Release of Interleukin-1β from Human Platelets Is Independent of NLRP3 and Caspase. Thromb Haemost. 2021 Jun 25. doi: 10.1055/s-0041-1731288.

Pennings GJ, Reddel CJ, Traini M, Campbell H, Chen V, Kritharides L. Colchicine inhibits ROS generation in response to glycoprotein VI stimulation. Scientific reports. 2021 Jun 7;11(1):1-3. DOI: 10.1038/s41598-021-91409-7.

Quach H, Lasica M, Routledge D, Kalff A, Lim A, Low M, Estell J, Sidiqi MH, Campbell P, Eek RW, Lai HC, McCaughan GJ, D'Rozario J, Browlett P, Rajagopal R, Heenan J, Murphy NE, RenwickW, Huan G, and Mollee P. A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand. Journal of Clinical Oncology 2021 May 28. DOI: 10.1200/JCO.2021.39.15_suppl.TPS8055.

Rabbolini D, Liang HP, Morel-Kopp MC, Connor D, Whittaker S, Dunkley S, Donikian D, Kondo M, Chen W, Stevenson WS, Campbell H, Chen VM. Building platelet phenotypes: diaphanous-related formin 1 (DIAPH1)-related disorder. Platelets. 2021 Jul 6:1-1. https://doi.org/10.1080/09537104.2021.1937593

Reddel CJ, Pennings GJ, Lau JK, Chen VM, Kritharides L. Circulating platelet?derived extracellular vesicles are decreased after remote ischemic preconditioning in patients with coronary disease: a randomized controlled trial. Journal of Thrombosis and Haemostasis. 2021 Jul 1. https://doi.org/10.1111/jth.15441 

Reddel CJ, Pennings GJ, Lau JK, Chen VM, Kritharides L. Circulating platelet-derived extracellular vesicles are decreased after remote ischemic preconditioning in patients with coronary disease: A randomized controlled trial. J Thromb Haemost. 2021 Oct;19(10):2605-2611. doi: 10.1111/jth.15441. Epub 2021 Aug 10.

Silver G, Krastev Y, Forbes MK, Hamdorf B, Lewis B, Tisbury M, Taylor MP, Gasiorowski R.Study protocol for a randomised controlled trial examining the effect of blood and plasma donation on serum perfluoroalkyl and polyfluoroalkyl substance (PFAS) levels in firefighters. BMJ Open. 2021 May 7;11(5):e044833. doi: 10.1136/bmjopen-2020-044833.

Simon Cheah,Julie K. Bassett,Fiona J. Bruinsma,Wendy Cozen,John L. Hopper,Harindra Jayasekara,Douglas Joshua,Robert J. MacInnis,H. Miles Prince,Claire M. Vajdic,Marina T. van Leeuwen,Nicole Wong Doo,Simon J. Harrison,Dallas R. English,Graham G. Giles,Roger L. Milne. Alcohol and tobacco use and risk of multiple myeloma: A case-control study. First published: 10 November 2021 https://doi.org/10.1002/jha2.337

Sueh-li Lim, John Reynolds, Hang Quach, Anna Hutchinson, Ian H Kerridge, Jane Estell, Wojt Janowski, Craig Thomas Wallington-Beddoe, Anna Kalff, Flora Yuen, Andrew Spencer, Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy, Blood, Volume 138, Supplement 1, 2021, Page 1665, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-152102.

Tam CS, Dimopoulos MA, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen RG, Song Y, Xu W, Zhu J, Li J, Qiu L, D'Sa S, Jurczak W, Cull G, Marlton P, Gottlieb DJ, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H, Zhu H, Chan WY, Cohen A, Novotny W, Huang J, Tedeschi A.Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. Blood Adv. 2021 Nov 1:bloodadvances.2021005621. doi: 10.1182/bloodadvances.2021005621. Online ahead of print.

Tam CS, Opat S, Simpson D, Cull G, Munoz J, Phillips TJ, Kim WS, Rule S, Atwal SK, Wei R, Novotny W, Huang J, Wang M, Trotman J; Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv 2021; 5 (12): 2577-2585 22June2021. doi: https://doi.org/10.1182/bloodadvances.2020004074

Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021 Nov;14(11):1329-1344. doi: 10.1080/17512433.2021.1978288. Epub 2021 Sep 20. PMID: 34491123 Review.

Tam, Constantine & Giannopoulos, Krzysztof & Jurczak, Wojciech & Šimkovi?, Martin & Shadman, Mazyar & Österborg, Anders & Laurenti, Luca & Walker, Patricia & Opat, Stephen & Chan, Henry & Ciepluch, Hanna & Greil, Richard & Tani, Monica & Trneny, Marek & Brander, Danielle & Flinn, Ian & Grosicki, Sebastian & Verner, Emma & Brown, Jennifer & Hillmen, Peter. (2021). SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood. 138. 396-396. 10.1182/blood-2021-148457.

Tam, Constantine & Verner, Emma & Lasica, Masa & Arbelaez, Alejandro & Browett, Peter & Soumerai, Jacob & Hilger, James & Fang, Yiqian & Huang, Jane & Simpson, David & Opat, Stephen & Cheah, Chan. (2021). Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib. Blood. 138. 1419-1419. 10.1182/blood-2021-148451.

Tan, S. Y. C.; Turner, J.; Kerin-Ayres, K.; Butler, S.; Deguchi, C.; Khatri, S.; Cunningham, I.; Wildbore, C.; Malalasekera, A.; Vardy, J. Implementing Patient Reported Outcome Measures (PROMS) in a multidisciplinary cancer survivorship clinical setting. Asia-Pacific Journal of Clinical Oncology ; 17(SUPPL 9):96-97, 2021. Artigo em Inglês | EMBASE | ID: covidwho-1598556 PMID: 31563263 DOI: 10.1016/j.jval.2019.04.1927.

Tishya Indran, Michael Swain, Jacqueline Widjaja, Flora Yuen, Hang Quach, Wojt Janowski, Anna Hutchinson, Craig Thomas Wallington-Beddoe, Jane Estell, Ian H Kerridge, Andrew Spencer, The Effect of Daratumumab, Lenalidomide, Dexamethasone (DRd) on Peripheral Blood Stem Cell Mobilisation (PBSC), Blood, Volume 138, Supplement 1, 2021, Page 3884, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-150444.

Tohidi-Esfahani I, Tan S, Tan CW, Johnson L, Marks DC, Chen V. Platelet procoagulant potential is reduced in platelet concentrates ex vivo but appears restored following transfusion. Transfusion. 2021 Dec;61(12):3420-3431. doi: 10.1111/trf.16695. Epub 2021 Oct 5.

Tohidi-Esfahani I, Warden A, Malunis E, DeNardis PL, Haurat J, Black M, Opat S, Kee D, D'Sa S, Kersten MJ, Spearing RL, Palomba ML, Olszewski AJ, Harrington C, Scott CL, Trotman J. WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes. Am J Hematol. 2021 Jun 1 https://doi.org/10.1002/ajh.26173

Torben Plesner, Simon J Harrison, Hang Quach, Cindy H. Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick Twomey, Voleak Choeurng, Junyi Li, Robert Hendricks, Teiko Sumiyoshi, Karen Miller, Eunpi Choi, Fredrik H. Schjesvold, A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), Blood, Volume 138, Supplement 1, 2021, Page 2755, ISSN 0006-4971, https://doi.org/10.1182/blood-2021-147418.

Trotman J, Barrington SF. The role of PET in first-line treatment of Hodgkin lymphoma. Lancet Haematol. 2021 Jan 8 https://doi.org/10.1016/s2352-3026(20)30357-43.

Trotman J, Buske C, Tedeschi A, Matous JV, MacDonald D, Tam CS, Tournilhac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-Hisijara I, Dimopoulos MA. Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial. Clin Cancer Res. 2021 Nov 1; 27(21):5793-5800. doi: 10.1158/1078-0432.CCR-21-1497. Epub 2021 Aug 11.

Trotman J, Hokland P. Correspondence in reference to the previously published Epub manuscript: "Peter Hokland, et al. How I treat advanced Hodgkin lymphoma - a global view. British Journal of Haematology 2020; 190: 837-850." - RESPONSE. Br J Haematol. 2021 Apr;193(1):e4-e5. Epub 2021 Feb 22.

Trotman J, Pettitt AR; Is it time for PET-guided therapy in follicular lymphoma. Blood 2021. ISSN 0006-4971, https://doi.org/10.1182/blood.2020008243.

Wight, J & Hamad, Nada & Campbell, B.A & Ku, Matthew & Lee, K & Rose, H & Armytage, T & Latimer, Maya & Lee, HP & Lee, ST & Dickinson, Michael & Khor, R & Verner, Emma. (2021). Diffuse large B?cell lymphoma: A consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 10.1111/imj.15533.

Haematology Research

Our Key Research Themes and Achievements

Patient and Community Philanthropic Support

MyHodgkin MyHealth

Our Research Team

Selected Grants

Our Publications

2023

Haematology Research

Haematology Research

Our Organisation

Make a Donation

Our Hospitals

Right to Information

Plans

Publications

Quick Links